Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07354308

Study to Evaluate the Efficacy of an Avocado Dietary Supplement

This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults. The study includes body measurements, questionnaires, blood tests, and CGM monitoring to assess metabolic outcomes and participant-reported perceptions of well-being.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Overweight Body Weight Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Metabolic Health Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89118, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be male or female
  • Be aged between 18 and 70 years of age
  • Be classified as overweight or obese with a BMI of ≥25.0 and ≤32 kg/m2.
  • Have a stable weight defined as <10% change in body weight in three months prior to the study start date.
  • Willing to follow the provided diet and exercise guidelines.
  • Willing to not consume avocados throughout the trial and for two weeks prior to Baseline
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
  • Willing to stop any products, any prescription medication, or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period.
  • Willing to avoid introducing any new products or any new forms of prescription medication or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period.
  • Not currently partaking in another research study and will not be partaking in any other research study for the next 16 weeks and at any point during this study's duration.
  • Must have someone available to take front and side profiles of the torso.
  • Must have a smart phone or camera capable of taking photos of the torso.
  • Resides in the United States.

Exclusion criteria

  • Anyone with diagnosed Type I or Type II diabetes.
  • Allergic to avocados
  • Anyone with any allergies or sensitivities to any of the study product ingredients.
  • Any women who are pregnant, breastfeeding, or trying to conceive
  • Anyone unwilling to follow the study protocol.
  • Has stopped using hormonal birth control in the past month.
  • Anyone with a history of substance abuse.
  • Anyone who is currently a smoker or has been a smoker in the past 6 months.
  • Anyone with chronic health conditions that could impact participation in the study, such as oncological, psychiatric, metabolic, hypertension, or cardiovascular disorders, cancer, autoimmune disease, HIV, Hepatitis B, and/or C, kidney and/or liver, gastrointestinal, gastroesophageal reflux, blood/bleeding disorders, gout, or mental health disorders.
  • Anyone who has had any major illness in the last 3 months.
  • Anyone who drinks heavily (i.e., 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
  • Current use of prescribed medications as listed below: Weight loss prescription medication (within 3 months of baseline). Anticoagulants and coagulants (within 4 weeks of baseline).
  • Anyone who has used any cannabis products (medical or recreational) in the past month.

Treatment and study plan

Metavo Supplement

Dietary Supplement

Participants will take 8 Intervention capsules per day (4 in the morning, 4 in the afternoon)

Placebo

Dietary Supplement

Participants will take 8 placebo capsules per day (4 in the morning, 4 in the afternoon)

Primary outcomes

  1. Change in Body Mass

    Time frame: Baseline through Week 16

    Measured via Withings Smart Scale. Participants will weigh themselves daily for 3 consecutive days each week. If the first two values are similar, their average is used. If they differ by ≥10 lbs, the third value is used to determine the average.

  2. Change in Average Blood Glucose

    Time frame: 2 weeks before Baseline and Weeks 14-16

    Change in average blood glucose levels measured using a Continuous Glucose Monitor (CGM). Average glucose will be calculated over each time period and the change from pre-baseline to Weeks 14-16 will be reported.

  3. Change in Hemoglobin A1C (HbA1C)

    Time frame: Baseline and Week 16

    Assessed via blood samples at Labcorp or via home phlebotomy.

  4. Change in Fasting Insulin

    Time frame: Baseline and Week 16

    Assessed via blood samples at Labcorp or via home phlebotomy.

  5. Change in Lipid Panel

    Time frame: Baseline and Week 16

    Includes Cholesterol, LDL, VLDL, HDL, and triglycerides. Measured via Labcorp or home phlebotomy.

  6. Change in hs-CRP

    Time frame: Baseline and Week 16

    High-sensitivity C-reactive protein measured via Labcorp or home phlebotomy.

  7. Change in Fasting GLP-1 Levels

    Time frame: Baseline and Week 16

    Only measured in the home phlebotomy subgroup using InterScience Institute lab testing.

  8. Change in Waist Circumference

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

    Measured with a tape measure.

  9. Change in Time in Range (TIR)

    Time frame: 2 weeks before Baseline and Weeks 14-16

    Change in percentage of time that glucose levels are within the target range, measured using a CGM. TIR will be computed as the percentage of total CGM readings within the target range during the specified time periods.

  10. Change in Time Below Range (TBR)

    Time frame: 2 weeks before Baseline and Weeks 14-16

    Change in percentage of time that glucose levels are below the target range, measured using a CGM. TBR will be calculated as the percentage of total CGM readings below the target range.

  11. Change in Time Above Range (TAR)

    Time frame: 2 weeks before Baseline and Weeks 14-16

    Change in percentage of time that glucose levels are above the target range, measured using a CGM. TAR will be calculated as the percentage of total CGM readings above the target range.

Secondary outcomes

  1. Change in Quality of Life

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

    Evaluated using the Short Form-12 (SF-12) questionnaire.

  2. Change in Physical Activity

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

    Evaluated using the Godin Leisure-Time Exercise Questionnaire (GLTE).

  3. Change in Eating Habits

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

    Evaluated using the Three-Factor Eating Questionnaire - Revised 21 (TFEQ-R21).

  4. Change in Food Cravings

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

    Evaluated using the Food Craving Questionnaire - Trait reduced (FCQ-T reduced).

  5. Change in Self-Reported Mood, Energy, and Health

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

    Participants report changes in energy levels, weight perception, mood, and general well-being.

  6. Change in Total Muscle Mass (kg)

    Time frame: Weekly from Baseline to Week 16

    Total skeletal muscle mass measured in kilograms using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).

  7. Change in Total Body Fat Mass (kg)

    Time frame: Weekly from Baseline to Week 16

    Total weight of body fat measured in kilograms using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).

  8. Change in Bone Mass (kg)

    Time frame: Weekly from Baseline to Week 16

    Estimated weight of bone mineral content in kilograms, measured using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).

  9. Change in Total Lean Mass (kg)

    Time frame: Weekly from Baseline to Week 16

    Total fat-free mass (including muscle, bone, and water) measured in kilograms using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).

  10. Change in Total Body Water Percentage (%)

    Time frame: Weekly from Baseline to Week 16

    Total body water as a percentage of total body weight, measured using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).

  11. Change in Visceral Fat Index

    Time frame: Weekly from Baseline to Week 16

    An indexed score representing the amount of visceral fat (the fat surrounding internal organs) measured via a Withings smart scale. This index typically ranges from 1 to 20, where higher scores indicate higher visceral fat levels.

Sponsors and collaborators

Lead sponsor

SP Nutraceuticals Inc.

Industry

Collaborators

  • Citruslabs

Registry information

Official study title

A Study to Evaluate the Efficacy of an Avocado Dietary Supplement to Support Healthy Weight and Blood Glucose Management

Acronym: METAVO-ONE

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 21, 2026
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.